image
Healthcare - Medical - Devices - NYSE - US
$ 112.54
3.39 %
$ 22.4 B
Market Cap
21.48
P/E
1. INTRINSIC VALUE

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products.[ Read More ]

The intrinsic value of one ZBH stock under the base case scenario is HIDDEN Compared to the current market price of 113 USD, Zimmer Biomet Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ZBH

image
FINANCIALS
7.39 B REVENUE
6.55%
1.28 B OPERATING INCOME
20.07%
1.02 B NET INCOME
251.65%
1.58 B OPERATING CASH FLOW
23.11%
-779 M INVESTING CASH FLOW
-47.18%
-764 M FINANCING CASH FLOW
9.52%
1.82 B REVENUE
-6.07%
280 M OPERATING INCOME
-16.69%
249 M NET INCOME
2.64%
396 M OPERATING CASH FLOW
7.12%
-155 M INVESTING CASH FLOW
37.29%
-102 M FINANCING CASH FLOW
-10.88%
Balance Sheet Decomposition Zimmer Biomet Holdings, Inc.
image
Current Assets 4.61 B
Cash & Short-Term Investments 416 M
Receivables 1.44 B
Other Current Assets 2.75 B
Non-Current Assets 16.9 B
Long-Term Investments 5.4 M
PP&E 2.26 B
Other Non-Current Assets 14.6 B
Current Liabilities 2.86 B
Accounts Payable 411 M
Short-Term Debt 1.01 B
Other Current Liabilities 1.44 B
Non-Current Liabilities 6.15 B
Long-Term Debt 5.04 B
Other Non-Current Liabilities 1.11 B
EFFICIENCY
Earnings Waterfall Zimmer Biomet Holdings, Inc.
image
Revenue 7.39 B
Cost Of Revenue 2.08 B
Gross Profit 5.31 B
Operating Expenses 3.28 B
Operating Income 1.28 B
Other Expenses 254 M
Net Income 1.02 B
RATIOS
71.82% GROSS MARGIN
71.82%
17.28% OPERATING MARGIN
17.28%
13.85% NET MARGIN
13.85%
8.20% ROE
8.20%
4.76% ROA
4.76%
6.71% ROIC
6.71%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Zimmer Biomet Holdings, Inc.
image
Net Income 1.02 B
Depreciation & Amortization 952 M
Capital Expenditures -689 M
Stock-Based Compensation 99.8 M
Change in Working Capital -396 M
Others -50 M
Free Cash Flow 892 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Zimmer Biomet Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for ZBH of $128 , with forecasts ranging from a low of $110 to a high of $150 .
ZBH Lowest Price Target Wall Street Target
110 USD -2.26%
ZBH Average Price Target Wall Street Target
128 USD 13.86%
ZBH Highest Price Target Wall Street Target
150 USD 33.29%
4. DIVIDEND ANALYSIS
0.23% DIVIDEND YIELD
0.24 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Zimmer Biomet Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
1.47 M USD 1
6-9 MONTHS
3.58 M USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
5 months ago
May 31, 2024
Sell 1.47 M USD
Yi Sang
Group President, Asia Pacific
- 12857
114.691 USD
8 months ago
Mar 07, 2024
Sell 216 K USD
Yi Sang
Group President, Asia Pacific
- 1705
126.86 USD
8 months ago
Feb 22, 2024
Sell 3.29 M USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 25546
128.6067 USD
8 months ago
Feb 22, 2024
Sell 78.7 K USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 610
129.0807 USD
1 year ago
Nov 09, 2023
Bought 224 K USD
Jafry Syed A.
Director
+ 2135
104.75 USD
1 year ago
Aug 28, 2023
Bought 117 K USD
BEGLEY CHRISTOPHER B
Director
+ 1000
117.114 USD
1 year ago
Aug 30, 2023
Bought 120 K USD
Kolli Sreelakshmi
Director
+ 1000
120.37 USD
1 year ago
Aug 28, 2023
Bought 233 K USD
HAGEMANN ROBERT
Director
+ 2000
116.48 USD
1 year ago
Aug 25, 2023
Bought 150 K USD
MICHELSON MICHAEL W
Director
+ 1300
115.5 USD
1 year ago
Aug 25, 2023
Bought 100 K USD
BERNARD BETSY J
Director
+ 871
114.8364 USD
6 years ago
Mar 20, 2018
Bought 16.8 K USD
BERNARD BETSY J
Director
+ 150
111.8867 USD
1 year ago
Aug 23, 2023
Bought 57.3 K USD
HIGGINS ARTHUR J
Director
+ 500
114.6751 USD
1 year ago
Aug 23, 2023
Bought 58.3 K USD
HIGGINS ARTHUR J
Director
+ 500
116.55 USD
1 year ago
Mar 17, 2023
Sell 2.46 M USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 19743
124.402 USD
1 year ago
Mar 17, 2023
Sell 413 K USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 3302
125.089 USD
1 year ago
Dec 13, 2022
Sell 1.34 M USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 10459
128.5578 USD
1 year ago
Dec 13, 2022
Sell 137 K USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 1063
129.344 USD
2 years ago
Jul 01, 2022
Sell 55.9 K USD
VAN ZUILEN WILFRED
Pres, Europe, M. East & Africa
- 531
105.217 USD
2 years ago
Mar 17, 2022
Sell 3.6 M USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 29518
121.8996 USD
2 years ago
Dec 14, 2021
Sell 323 K USD
Yi Sang
President, Asia Pacific
- 2600
124.14 USD
2 years ago
Dec 14, 2021
Sell 24.8 K USD
Yi Sang
President, Asia Pacific
- 200
124.175 USD
3 years ago
May 06, 2021
Bought 172 K USD
HIGGINS ARTHUR J
Director
+ 1000
171.58 USD
4 years ago
Nov 18, 2020
Sell 183 K USD
Yi Sang
President, Asia Pacific
- 1200
152.59 USD
4 years ago
Nov 09, 2020
Sell 4.8 M USD
Phipps Chad F
Sr. VP/Gen Counsel/Secretary
- 30040
159.7 USD
4 years ago
May 29, 2020
Sell 376 K USD
Yi Sang
President, Asia Pacific
- 3000
125.3767 USD
4 years ago
May 13, 2020
Bought 113 K USD
Hanson Bryan C
President and CEO
+ 1000
113 USD
7. News
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace. zacks.com - 5 days ago
Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts On Wednesday, Zimmer Biomet Holdings, Inc ZBH reported third-quarter adjusted EPS of $1.74, up from $1.65 a year ago, in line with the Street estimates. benzinga.com - 2 weeks ago
ZBH Stock Up Despite Q3 Earnings Miss, 2024 View Narrowed Zimmer Biomet delivers strong performance across segments and regions in the third quarter of 2024. zacks.com - 2 weeks ago
Zimmer Biomet Holdings, Inc. (ZBH) Q3 2024 Earnings Call Transcript Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants David DeMartino – Senior Vice President-Investor Relations Ivan Tornos – President and Chief Executive Officer Suketu Upadhyay – Chief Financial Officer and Executive Vice President-Finance, Operations and Supply Chain Conference Call Participants Travis Steed – Bank of America Vik Chopra – Wells Fargo David Roman – Goldman Sachs Allen Gong – JPMorgan Matthew O'Brien – Piper Sandler Chris Pasquale – Nephron Steve Lichtman – Oppenheimer Sophia Knopp – Evercore ISI Richard Newitter – Truist Securities Jeff Johnson – Baird Caitlin Cronin – Canaccord Mike Matson – Needham & Company Shagun Singh – RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today, October 30, 2024. seekingalpha.com - 2 weeks ago
Zimmer (ZBH) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 weeks ago
Implant maker Zimmer Biomet lowers full-year profit forecast Hip implant maker Zimmer Biomet lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations. reuters.com - 2 weeks ago
Zimmer Biomet (ZBH) Misses Q3 Earnings Estimates Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago. zacks.com - 2 weeks ago
What to Expect From These 3 MedTech Stocks This Earnings Season Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow. zacks.com - 2 weeks ago
Countdown to Zimmer (ZBH) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Evaluate the expected performance of Zimmer (ZBH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 2 weeks ago
Zimmer Biomet to Debut New Z1™ Femoral Hip System and Clinical Data on G7® Acetabular System at 2024 AAHKS Annual Meeting Company's Booth Spotlights Comprehensive Hip Portfolio and Enabling Technologies Including OrthoGrid Hip AI® and HAMMR™ Automated Hip Impaction System WARSAW, Ind. , Oct. 28, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced plans for the broad commercial launch of the Z1™ Femoral Hip System (Z1 System) for total hip arthroplasty at the 2024 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS). prnewswire.com - 2 weeks ago
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock? Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET. zacks.com - 1 month ago
8. Profile Summary

Zimmer Biomet Holdings, Inc. ZBH

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 22.4 B
Dividend Yield 0.23%
Description Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Contact 345 East Main Street, Warsaw, IN, 46580 https://www.zimmerbiomet.com
IPO Date July 25, 2001
Employees 18000
Officers Mr. Suketu P. Upadhyay Chief Financial Officer and Executive Vice President of Finance, Operations & Supply Chain Mr. Paul A. Stellato Vice President, Controller & Chief Accounting Officer Ms. Rachel H. Ellingson Senior Vice President & Chief Administrative Officer Mr. David M. DeMartino Senior Vice President of Investor Relations Mr. Shaun Braun Senior Vice President & Chief Information and Technology Officer Mr. Ivan Tornos Chief Operating Officer, President, Chief Executive Officer & Director Mr. Sang Yi President of Asia Pacific Ms. Angela Main Senior Vice President, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific Ms. Lori Winkler Senior Vice President & Chief Human Resources Officer Mr. Wilfred van Zuilen Group President of Europe, Middle East & Africa